fda approves first oral glp-1 obesity drug august 1 2025 FDA Grants Speedy Approval to

Other GLP-1R agonists have demonstrated extensive pleiotropic effects, including benefits in managing comorbidities such as osteoarthritis, cardiovascular disease, and neurodegenerative disorders

Check our post How Prescription Coverage Works to get the full list of tips

While this study doesnt specifically look at eating disorders, it does suggest that people with eating disorders may be more likely to seek out GLP-1 medications

In CVOTs, liraglutide, semaglutide and dulaglutide demonstrated appreciable cardiovascular and renal protective effects, among which liraglutide had an appreciable effect on mitigating the risk of cardiovascular death [4], while semaglutide and dulaglutide conferred a risk reduction on non-fatal stroke [22, 23]